Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes.
The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the 'SEC') on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@allianceg.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Forward-Looking Statements
This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company's Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
REVIVA CONTACTS:
Corporate Contact:Reviva Pharmaceuticals Holdings, Inc.Laxminarayan Bhat, PhDwww.revivapharma.com
Investor Relations Contact:LifeSci Advisors, LLCPJ Kelleherpkelleher@lifesciadvisors.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
iSpecimen's $6M Valuation Doesn't Reflect the Business-Let Alone the $200M Treasury (NASDAQ: ISPC)
WOBURN, MA / / August 20, 2025 / A share price of $1.11. A $6.1 million market cap. Just 5.54 million shares outstanding. And a newly announced $200 million digital treasury. On paper, the disconnect between price and intrinsic value, let alone inherent potential, is hard to miss. But the real takeaway isn't just the contrast. It's what that contrast says about iSpecimen Inc. (NASDAQ:ISPC): a company with a functioning platform, measurable revenue, and real-world utility that remains miscategorized and underpriced by the market.(ISPC Share count and price data on 8/20/2025) The digital treasury announcement deserved headlines. It's rare for any microcap, especially in life sciences, to unveil a capital strategy of that scale. But the attention came with a surprising market reaction. Following the news, ISPC shares moved lower. That drop wasn't tied to any breakdown in the business. It was likely due to timing. The news hit after-hours, when retail investors had little access and institutions hadn't yet responded. What the market saw was the number. What it didn't see was the system behind it. Solving the Bottleneck in Life Sciences iSpecimen is not a clinical-stage biotech, nor is it speculative software. It operates a fully functional digital marketplace for human biospecimens-vital inputs for both preclinical and clinical research. The platform allows researchers to efficiently source high-quality, well-characterized specimens with full traceability and regulatory compliance. Blood, plasma, tissue, and genomically sequenced material are the raw materials of discovery, yet sourcing them has long been a fragmented, manual, and inefficient process. iSpecimen fixes that. Its proprietary, cloud-based platform lets researchers search, filter, and request exactly what they need based on disease state, demographic, clinical history, or processing requirements. On the other end, hospitals and labs can monetize excess inventory. iSpecimen handles compliance, logistics, and invoicing. The result is a streamlined transaction that unlocks value for both sides. This isn't a roadmap or beta test. The platform is live, and it's producing revenue. In 2024, the company posted $9.29 million in revenue. That number didn't come from grants or one-time licensing. It came from platform activity, repeated use, and institutional adoption. The Treasury is Not a Gimmick - It's a Strategic Asset The $200 million digital treasury that sparked attention isn't accounted for as cash on the balance sheet. But that doesn't mean it lacks financial weight. It is a capital preservation and liquidity strategy built to support long-term operations. Built on Solana, it features insured custody, cold storage, and a risk-managed structure that removes reliance on traditional capital markets. This isn't a distraction. It's financial insulation. It allows iSpecimen to grow without falling into the trap of repeated, dilutive financing. That kind of flexibility, especially for a microcap, is rare. But while the market focused on that headline, it missed the infrastructure behind it. iSpecimen's core business is still the real story. Expanding Reach Across Critical Therapeutic Areas Behind the scenes, the company is scaling its footprint across several high-value segments of medicine. In cancer research, it's now working with U.S.-based oncology centers and a genomic sequencing partner to deliver hard-to-source biospecimens for precision studies. In women's health, iSpecimen has access to over 600,000 patients through multi-state partnerships, unlocking samples across reproductive, hormone, and breast health. And in early 2025, the company proactively secured sourcing for human metapneumovirus (hMPV), anticipating potential waves of global research interest. Each of these initiatives adds operational depth to a platform that was already delivering. None of it would matter if the core system didn't work. But it does, and the results are increasingly visible. When the Market Doesn't Know Where to Look The mispricing here may stem from the fact that iSpecimen doesn't fit cleanly into a familiar category. It's not chasing regulatory approval, so it doesn't trade on FDA calendars. It's not a SaaS company, though its platform behaves like one. Instead, it sits between logistics, life sciences, and digital infrastructure - and that ambiguity often delays recognition. But that's also where value hides. iSpecimen runs an asset-light, transaction-based model. It doesn't need to build labs or develop its own trial pipeline. It monetizes what already exists by organizing and standardizing the connections between researchers and providers. That model is scalable across disease areas, institutions, and even global geographies. This Isn't a Bet. It's a Repricing in Progress The treasury may have been the headline, but it isn't the whole story. It's simply a structural advantage layered onto a business that is already performing. The marketplace, the revenue, the partnerships, and the platform all existed before the $200 million plan was announced. Thus, ISPC isn't a company hoping for validation. It's a company that already has it - just not from the market yet. At $1.11, the share price reflects none of that. But that doesn't mean the value isn't there. It just means the recognition hasn't arrived yet. When it does, the most temporary number in this entire story might be the one investors are staring at right now. *Reprinted with permission from Hawk Point Media Group, LLC. About iSpecimen iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact:Investor Contactsinfo@ For this content only: info@ Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated five thousand dollars to create this content as part of a more extensive digital marketing program by IR Agency, Inc. Accordingly, this content may be reused and syndicated beyond the channels used by Hawk Point Media, LLC. This disclaimer and the link to the broader disclosures must be part of all reproductions. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in iSpecimen Inc. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment. SOURCE: iSpecimen, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
a minute ago
- Yahoo
2030 financial targets announced: Organic sales growth acceleration, margin expansion and ROIC improvement
COPENHAGEN, Denmark - August 20, 2025. Novonesis today announces its 'GROW' strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end-markets with strong capabilities to deliver value-adding solutions for tailored customer needs. Novonesis' distinct position is built on three capabilities: deep customer understanding, unparalleled innovation and an exceptional ability to scale and produce robust and affordable biosolutions. In a world with a growing population, increasing energy needs, evolving nutritional and health trends, as well as climate risks, the company sees a strong and increasing demand for biosolutions. Ester Baiget, President & CEO: 'We are clearly on track to deliver on our 2025 targets that were set when we announced the combination. The potential for biosolutions continues to be strong and Novonesis is uniquely positioned to achieve accelerated profitable growth towards 2030 and beyond. We focus on growing our core, where we continue to see strong demand, and we significantly invest in our distinct capabilities to further expand our market and innovation leadership. We believe the more we grow, the more long-term value and impact we create for shareholders, customers, people and the planet.' Novonesis' proven growth matrix is a well-balanced combination of end-market volume growth, pricing, upselling and adjacencies, as well as penetration. The company continues to explore areas with long-term growth opportunities targeting applications and markets with significant untapped potential. The new explorative areas in focus are Biopharma Processing Aids, Future Fuels and Chemicals, and Functional Food Proteins. 2030 targets* Organic sales growth CAGR of 6-9%. The organic sales growth is expected to be mainly driven by volume, including synergies, as well as an annual price contribution between 1-2%. Both the Food & Health and Planetary Health Biosolutions divisions are expected to grow within the Group range, and emerging markets are expected to grow stronger than developed markets. An adjusted EBITDA margin expected at around 39% by 2030, based on current currency exchange rates. The strategy period includes synergies, as well as significant investments in innovation, commercial and go-to-market capabilities to support growth on both the short- and long-term time horizons. The adjusted ROIC excl. goodwill is expected at around 16% by 2030, increasing from pro forma 8.3% in 2024. A reconfirmation of non-financial ambitions and targets, with investments to realize these targets. Modeling assumptions* Capex as a percentage of sales will be elevated at the beginning of the strategy period to cater for sustained high growth, also beyond the strategy period. A new ERP system and investments to support sustainability efforts are also included in the Capex. We invest globally to cater for increasing demand, creating flexibility on a global and regional basis. The Capex level will gradually decrease to high-single-digit as a percent of sales towards the end of the strategy period. A net debt/EBITDA ratio is targeted at around 1.5x in alignment with the capital allocation policy. A continued clear capital allocation model with an expected dividend payout ratio of 40-60% of adj. net profit. The 2030 strategy will be presented and commented on in combination with the extended H1 2025 conference call on August 21 at 09.00 CET. Slides will be shared ahead of the conference call. * 2025 as a baseline. All targets assume constant currencies, no impact from acquisitions or divestments, no major changes or disruptions to the current state of the global economy, including global trade conditions. Contact information Investor Relations Tobias Bjorklund, +45 3077 8682, tobb@ Anders Enevoldsen, +45 5350 1453, adev@ Katrine Spedtsberg Poulsen, kats@ Media Relations Jens Gamborg, +45 3077 7182, jgam@ Forward-looking statements This announcement includes forward-looking statements, including statements relating to the operating, financial and sustainability performance and results of the group and/or the industry in which it operates. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words such as "aim", "anticipate", "assess", "assume", "believe", "continue", "could", "estimate", "expect", "goal", "hope", "intend", "may", "objective", "plan", "position", "potential", "predict", "project", "risk", "seek", "should", "target", "will", "would", or any variations of such words or other words with similar meanings. Any such statements are subject to risks and uncertainties that could cause the group's actual results to differ materially from the results discussed in such forward-looking statements. Prospective information is based on management's then current expectations or forecasts. Such information is subject to the risk that such expectations or forecasts, or the assumptions underlying such expectations or forecasts, may change. Unless as required by applicable laws, the group assumes no obligation to update any such forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements. Factors that could cause the group's actual results to differ materially from those expressed in its forward-looking statements include, but are not limited to: i) unexpected developments in the ability to develop and market new products; ii) fluctuations in the demand for the group's products, market-driven price decreases, industry consolidation, and launches of competing products or disruptive technologies in the group's core business areas; iii) changes in the ability to protect and enforce the company's intellectual property rights; iv) significant litigation or breaches of contract; v) the materialization of the company's growth platforms; vi) political conditions, such as acceptance of enzymes produced by genetically modified organisms; vii) global economic and capital market conditions, including, but not limited to, currency exchange rates (USD/DKK and EUR/DKK in particular, but not exclusively), interest rates, and inflation; viii) significant price decreases for input and other materials that compete with the group's solutions; and ix) changes in laws or interpretations thereof, including those related to reimbursement, intellectual property protection, marketing, and taxation (including tariffs and duties). New risk factors can arise, and it may not be possible for management to predict all such risk factors, nor to assess the impact of all such risk factors on the group's business or the extent to which any individual risk factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as predictions of actual future events or in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 minutes ago
- Business Wire
Deadline Approaching: KinderCare Learning Companies, Inc. (KLC) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased KinderCare Learning Companies, Inc. ('KinderCare' or the 'Company') (NYSE: KLC) common stock pursuant and/or traceable to the Company's October 2024 initial public offering (the 'IPO'). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN KINDERCARE LEARNING COMPANIES, INC. (KLC), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? In October of 2024, KinderCare conducted its IPO, selling over 27 million shares of common stock at $24 per share. On April 3, 2025, the Bear Cave published a report alleging, among other things, that KinderCare 'fails to deliver the safe and nurturing environment it promises parents and taxpayers' and is 'a broken business that harms the children and families it claims to help.' Specifically, the report detailed several incidents of child neglect and abuse that had occurred at KinderCare daycares and stated that on several occasions, individuals employed by KinderCare were later arrested on charges of child sex abuse. On this news, KinderCare's stock price fell $1.59, or 12.4%, to close at $11.19 per share on April 3, 2025, thereby injuring investors. Then, on June 5, 2025, the Bear Cave published a second report stating that 'allegations against [KinderCare] are growing, [and] lawmakers are demanding accountability.' Specifically, the report cited a statement from a congresswoman questioning the continued federal funding of KinderCare. On this news, KinderCare's stock price fell $0.63, or 5.5%, to close at $10.78 per share on June 5, 2025, thereby injuring investors further. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Registration Statement, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that numerous incidents of child abuse, neglect, and harm had occurred at KinderCare facilities; (2) that KinderCare did not provide the 'highest quality care possible' at its facilities, and, indeed, in numerous instances had failed to provide even basic care, meet minimum standards in the child care industry, or comply with the laws and regulations governing the care of children; (3) that, as a result of the foregoing, KinderCare was exposed to a material, undisclosed risk of lawsuits, adverse regulatory action, negative publicity, reputational damage, and business loss; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired KinderCare common stock pursuant and/or traceable to the IPO, you may move the Court no later than October 14, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
